Researchers halt enrollment in ReoPro stroke trial
Citing safety concerns, Centocor and Eli Lilly have halted enrolling patients for a trial of ReoPro for acute strokes. Some patients in the trial experienced bleeding inside the skull. The trial, which was launched in October '03, looked at using ReoPro to dissolve blood clots. ReoPro is approved for reducing chest pain prior to procedures.
- read this AP article for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
